Narrative review / 2020
A review discusses NAD+ metabolism and the progress of NAD+-boosting therapies in cardiovascular diseases linked to sudden cardiac death.
This review examines the fundamentals of NAD+ homeostasis and its role as a co-substrate for proteins such as sirtuins, poly(ADP-ribose) polymerases, and cyclic ADP-ribose synthetases. It covers molecular physiology and recent advances in ischemic-reperfusion injury, heart failure, and arrhythmias associated with sudden cardiac death risk. Additionally, the authors summarize the progress of NAD+-boosting therapy in human cardiovascular diseases and discuss challenges for future studies.
- Study type
- Narrative review
- Who was studied
- Human and preclinical models of cardiovascular disease
- What was measured
- NAD+ homeostasis and therapy in cardiovascular diseases
THE PAPER
NAD+ Metabolism as an Emerging Therapeutic Target for Cardiovascular Diseases Associated With Sudden Cardiac Death.
Xu W, Li L, Zhang L. Front Physiol, 2020.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.